SCHEMBL2228275

SCHEMBL2228275

COCCCNc1ncc(-c2cccc(Nc3ccc(Cl)cn3)n2)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.46
CCNT1 O60563 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 5/20 0.35
KMT2A Q03164 5/20 0.35
MAPT P10636 3/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
KDM4E B2RXH2 2/20 0.34
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ALDH1A1 P00352 1/20 0.34
RECQL P46063 1/20 0.34
ROS1 P08922 1/20 0.33
KCNH3 Q9ULD8 1/20 0.33
PIM1 P11309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14680970 0.78 CCNT1 (0.36) KDRCCNT1SMN1; SMN2HTTMEN1
SCHEMBL2226110 0.76 SLC2A1 (0.44) KDRSMN1; SMN2HTTHSD17B10MEN1
SCHEMBL2229276 0.71 KDR (0.46) KDRSMN1; SMN2HTTHSD17B10MEN1
SCHEMBL2352796 0.69 GRM5 (0.41) KDRCCNT1SMN1; SMN2HTTMEN1
SCHEMBL14673765 0.69 ABL1 (0.39) CCNT1
SCHEMBL2228280 0.68 MAPT (0.34) KDRCCNT1SMN1; SMN2HTTHSD17B10
SCHEMBL4898748 0.68 SLC2A1 (0.50) KDRSMN1; SMN2HTTHSD17B10MEN1
SCHEMBL2226495 0.67 MEN1 (0.39) KDRSMN1; SMN2HTTHSD17B10MEN1
SCHEMBL4903020 0.66 SLC2A1 (0.51) KDRSMN1; SMN2HTTMEN1KMT2A
SCHEMBL3146384 0.66 PDE10A (0.40) KDRSMN1; SMN2HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP claimed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US claimed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US claimed
EP-2523952-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB Science (FR) 2012-11-21 EP claimed
WO-2011086085-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2011-07-21 WO claimed
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SYK, LTK, MERTK KDR 79/4885CCNT1 2633/4885SMN1; SMN2 3846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.